Halifax-based biopharmaceutical company Appili Therapeutics has agreed to be acquired by Virginia life sciences company Aditxt in a nearly $17-million CAD deal.
Aditxt, Inc (ADTX) to Acquire Appili Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical.